Literature DB >> 16866614

A review of nelfinavir for the treatment of HIV infection.

Montserrat Olmo1, Daniel Podzamczer.   

Abstract

Nelfinavir (NFV) is a protease inhibitor that has been widely used for several years for the treatment of HIV infection. This has led to extensive experience with NFV-containing regimens, in which the drug has shown prolonged viral suppression, good tolerability and a unique resistance profile. In recent years, several antiretroviral drugs with some advantages over NFV have been developed. Nevertheless, NFV has favourable characteristics that make it a suitable antiretroviral compound for many HIV-infected patients. It can be used in patients who do not tolerate ritonavir even at low doses, and it is well tolerated in pregnant women, has a low-grade interaction with methadone and may be well tolerated in hepatitis C virus-co-infected patients. In addition, its new simplified posology may contribute to improved adherence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16866614     DOI: 10.1517/17425255.2.2.285

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  4 in total

Review 1.  HIV protease inhibitors in pregnancy : pharmacology and clinical use.

Authors:  Nisha Andany; Mona R Loutfy
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

2.  HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

Authors:  Yenisey Alfonso; Lianet Monzote
Journal:  Open Med Chem J       Date:  2011-03-09

3.  Induction of suicidal erythrocyte death by nelfinavir.

Authors:  Rosi Bissinger; Sabrina Waibel; Florian Lang
Journal:  Toxins (Basel)       Date:  2015-05-08       Impact factor: 4.546

Review 4.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.